Mechanisms of interaction of a plasmalogenic analog of platelet-activating factor with human platelets.
The interaction of a plasmalogenic analog of platelet-activating factor (1-O-alk-1;-enyl-2-acetyl-sn-glycero-3-phosphocholine; 1-alkenyl-PAF) with human platelets was studied. 1-Alkenyl-PAF induced an increase in intracellular Ca2+ concentration and inhibition of adenylate cyclase at significantly higher concentrations than PAF. 1-Alkenyl-PAF inhibits PAF-induced platelet aggregation but has no effect on ADP- or thrombin-induced aggregation of human platelets. In contrast to PAF, 1-alkenyl-PAF increases [3H]PGE1 binding with human platelets. The properties of 1-alkenyl-PAF as an agonist or antagonist of PAF receptors apparently depend on its concentration in the cell medium. Under physiological conditions 1-alkenyl-PAF might be a natural PAF antagonist acting in the human cardiovascular system.
Kulikov
V I
VI
Research and Development Center for Medical Biotechnology, Ministry of Public Health of the Russian Federation, Moscow, 123182, Russia.
Muzya
G I
GI
D000067956:Adenylyl Cyclase Inhibitors; D000527:Alprostadil / Q000378:metabolism; D001381:Azepines / Q000494:pharmacology; D001792:Blood Platelets / Q000502:physiology*; D002118:Calcium / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007700:Kinetics; D010955:Plasmalogens / Q000502:physiology*; D010972:Platelet Activating Factor / Q000502:physiology*; D014230:Triazoles / Q000494:pharmacology
D000067956:Adenylyl Cyclase Inhibitors; D001381:Azepines; D010955:Plasmalogens; D010972:Platelet Activating Factor; D014230:Triazoles; C052518:WEB 2086; D000527:Alprostadil; D002118:Calcium